All In Biotech

Free tool

FAERS Monitor: Augtyro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218213 or its brand name (Augtyro, Repotrectinib). Reports on generic versions are filed under their own applications.

Reports

274

Serious

174

64% of reports

Hospitalization

68

Death reported

36

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness44
  • death28
  • nausea21
  • off label use19
  • neuropathy peripheral18
  • fatigue13
  • adverse event12
  • pain12
  • muscular weakness11
  • paraesthesia10
  • balance disorder9
  • diarrhoea9
  • gait disturbance9
  • pulmonary embolism9
  • anaemia8

Reports by year received

View as table
YearReports
20222
2024100
2025114
202658

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,885 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neuropathy peripheralSignal1814.59.3214
adverse eventSignal1210.05.789
balance disorderSignal98.04.248
muscular weaknessSignal117.44.255
pulmonary embolismSignal97.33.843
dizzinessSignal446.85.2216
paraesthesiaSignal104.92.727
gait disturbanceSignal93.61.915
anaemiaSignal83.21.610
deathSignal282.51.825
nauseaSignal212.01.410
off label use191.71.15
pain121.50.92
fatigue131.30.81
diarrhoea91.10.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.